Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.570 +0.050 (+3.29%)
Official Closing Price Updated: 8:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy
October 7, 2025 – In a move that sent ripples across both the biotechnology and cryptocurrency sectors, MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company... 
Via BreakingCrypto
Topics ETFs Economy
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
Via Stocktwits
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at BIO International Convention 2025
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group. 
Via Benzinga
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
From MAIA Biotechnology
Via Business Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces $1.08 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Private Placement of $2,715,000
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at Biotech Showcase 2025
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
From MAIA Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.